Download PDF
Thromb Haemost 2005; 93(04): 789-791
DOI: 10.1055/s-0037-1616781
Case Report
Schattauer GmbH

A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite

Nicolas Von Beckerath
1   Deutsches Herzzentrum, Technische Universität München, Munich, Germany
,
Dirk Taubert
2   Institut für Pharmakologie, Klinikum der Universität zu Köln, Cologne, Germany
,
Gisela Pogatsa-Murray
1   Deutsches Herzzentrum, Technische Universität München, Munich, Germany
,
Anna Wieczorek
1   Deutsches Herzzentrum, Technische Universität München, Munich, Germany
,
Edgar Schömig
2   Institut für Pharmakologie, Klinikum der Universität zu Köln, Cologne, Germany
,
Albert Schömig
1   Deutsches Herzzentrum, Technische Universität München, Munich, Germany
,
Adnan Kastrati
1   Deutsches Herzzentrum, Technische Universität München, Munich, Germany
› Author Affiliations
Further Information

Publication History

Received 12 October 2004

Accepted after resubmission 18 January 2005

Publication Date:
15 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Savi P, Pereillo JM, Uzabiaga MF. et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Hollopeter G, Jantzen HM, Vincent D. et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-7.
    CrossrefPubMedGoogle Scholar
  • 3 Gurbel PA, Bliden KP, Hiatt BL. et al. Clopidogrel for coronary stenting. Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13.
    CrossrefPubMedGoogle Scholar
  • 4 Müller I, Besta F, Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Matetzky S, Shenkman B, Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5.
    CrossrefPubMedGoogle Scholar
  • 6 Lau WC, Waskell LA, Watkins PB. et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-7.
    CrossrefPubMedGoogle Scholar
  • 7 Lau WC, Gurbel PA, Watkins PB. et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166-71.
    CrossrefPubMedGoogle Scholar
  • 8 Fontana P, Dupont A, Gandrille S. et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-95.
    CrossrefPubMedGoogle Scholar
  • 9 Taubert D, Kastrati A, Harlfinger S. et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004; 92: 311-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome p450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31: 53-9.
    CrossrefPubMedGoogle Scholar
  • 11 Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17.
    CrossrefPubMedGoogle Scholar
  • 12 Bjornsson TD, Callaghan JT, Einolf HJ. et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31: 815-32.
    CrossrefPubMedGoogle Scholar
  • 13 Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 2004; 26: 192-9.
    CrossrefPubMedGoogle Scholar